Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (¹⁷⁷Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, ¹⁷⁷Lu DOTATATE has been increasingly used as a treatment option for NETs. Less than 5 years later, in March 2022, ¹⁷⁷Lu vipivotide tetraxetan (PLUVICTO, Advanced Accelerator Applications) received FDA approval for the treatment of prostate-specific membrane antigen-positive castration-resistant metastatic prostate cancer. Both drugs are excellent examples of viable radiotheranostic therapies. As more radiotheranostic agents and applications get adopted in clinical practice, interventional radiologists are likely to get exposed to this field in a way or another. In this article, we discuss the fundamentals of radiotheranostic therapy and explore the expanding role interventional radiology (IR) is expected to play as an essential partner in modern oncology practice.

Publication History

Article published online:
20 December 2022

• References

• 1 Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys 2017; 4 (01) 15
• 2 Goldsmith SJ. Targeted radionuclide therapy: a historical and personal review. Semin Nucl Med 2020; 50 (01) 87-97
• 3 Herrmann K, Schwaiger M, Lewis JS. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol 2020; 21 (03) e146-e156
• 4 Hennrich U, Kopka K. Lutathera^®: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 2019; 12 (03) 114
• 5 Hope TA, Abbott A, Colucci K. et al. NANETS/SNMMI procedure standard for somatostatin receptor–based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med 2019; 60 (07) 937-943
• 6 Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. ¹¹¹In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med 2019; 60 (09) 1266-1269
• 7 Ramage JK, Ahmed A, Ardill J. et al; UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61 (01) 6-32
• 8 Strosberg JR, El-Haddad G, Al-Toubah T. et al. Radioembolization versus bland or chemoembolization for liver-dominant neuroendocrine tumors: Is it an either/or question?. J Nucl Med 2021; 62: 1669-1671
• 9 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. World J Gastroenterol 2017; 23 (15) 2640-2650
• 10 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
• 11 Cornelis FH, Durack JC, Morris MJ, Scher HI, Solomon SB. Effective prostate-specific membrane antigen-based ¹⁸F-DCFPyL-guided cryoablation of a single positive site in a patient believed to be more metastatic on ¹¹C-choline PET/CT. Clin Nucl Med 2017; 42 (12) e516-e518
• 12 Lohaus F, Zöphel K, Löck S. et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease?. Eur Urol 2019; 75 (04) 548-551
• 13 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020; 21 (01) 141
• 14 Sayman HB, Gulsen F, Sager S. et al. Selective intra-arterial lutetium-177-labeled prostate-specific membrane antigen therapy for castration-resistant prostate cancer: initial results. J Vasc Interv Radiol 2022; 33 (03) 342-345
• 15 Vonken EPA, Bruijnen RCG, Snijders TJ. et al. Intraarterial administration boosts ¹⁷⁷Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med 2022; 63 (03) 406-409
• 16 International Medical Graduates Alternate Pathway. American Board of Radiology Website. Accessed September 12, 2022 at: https://www.theabr.org/diagnostic-radiology/initial-certification/alternate-pathways/international-medical-graduates